RAD51 and prostate carcinoma: RAD51 has proved to be a predictive marker to therapeutic responses in various cancers, including platinum-based chemotherapy benefit in breast cancer [16], esophageal squamous cell carcinoma [18], PARP inhibitor benefit in pancreatic cancer [19] and prostate cancer [20].